Fri, July 12, 2024
[ 12:00 AM ] - WOPRAI
Fri, May 3, 2024
[ 12:00 AM ] - WOPRAI
Mon, March 11, 2024
[ 12:00 AM ] - WOPRAI
Wed, February 28, 2024
[ 12:00 AM ] - WOPRAI
Mon, February 12, 2024
[ 12:00 AM ] - WOPRAI
Mon, December 11, 2023
[ 12:00 AM ] - WOPRAI
Fri, November 10, 2023
[ 12:00 AM ] - WOPRAI
Mon, October 30, 2023
[ 12:00 AM ] - WOPRAI
Wed, October 11, 2023
[ 12:00 AM ] - WOPRAI
Mon, July 24, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 28, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 14, 2023
[ 12:00 AM ] - WOPRAI
Tue, January 31, 2023
[ 12:00 AM ] - WOPRAI
Mon, December 19, 2022
[ 12:00 AM ] - WOPRAI
Mon, December 5, 2022
[ 12:00 AM ] - WOPRAI
Tue, November 8, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, September 9, 2022
[ 12:00 AM ] - WOPRAI
Tue, August 16, 2022
[ 12:00 AM ] - WOPRAI
Tue, May 24, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, April 20, 2022
[ 12:00 AM ] - WOPRAI
Tue, April 12, 2022
[ 12:00 AM ] - WOPRAI
Fri, April 1, 2022
[ 12:00 AM ] - WOPRAI
Thu, February 3, 2022
[ 12:00 AM ] - WOPRAI
Tue, February 1, 2022
[ 12:00 AM ] - WOPRAI
Fri, December 17, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, November 23, 2021
[ 12:00 AM ] - WOPRAI
Tue, September 7, 2021
Chris Shibutani Maintained (AMLX) at Hold with Increased Target to $4 on, Jul 12th, 2024
Chris Shibutani of Goldman Sachs, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Hold with Increased Target from $3 to $4 on, Jul 12th, 2024.
Chris has made no other calls on AMLX in the last 4 months.
There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 2 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Graig Suvannavejh of "Mizuho" Maintained at Hold with Decreased Target to $3 on, Tuesday, May 14th, 2024
- Joel Beatty of "Baird" Maintained at Hold with Decreased Target to $3 on, Thursday, April 11th, 2024
This is the rating of the analyst that currently disagrees with Chris
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $8 on, Wednesday, July 10th, 2024
Contributing Sources